RECURSION PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
RECURSION PHARMACEUTICALS INC. - More news...
RECURSION PHARMACEUTICALS INC. - More news...
- Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
- Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
- Recursion and Exscientia Shareholders Approve the Proposed Combination
- Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
- Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
- Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
- Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
- Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
- CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
- Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
- Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
- Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
- Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
- Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
- Recursion Announces Proposed Offering of Class A Common Stock
- Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
- Recursion to Participate in Upcoming Investor Conferences
- Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
- Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
- Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
- Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
- Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
- Recursion to Participate in Upcoming Investor Conferences
- Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
- Recursion to Participate in Upcoming Investor Conference
- Recursion Publishes Annual Environmental, Social and Governance Report
- Recursion Announces Plans to Open New Office in London
